{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 38,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a structured list format to categorize different types of competitive moats (regulatory, patent, strategic, and operational).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/11",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.39,
        "x": 0.57,
        "y": 0.14
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c96a28ce-dae4-46b7-8d95-23090fa0195c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.04,
        "y": 0.54
      },
      "kind": "list",
      "text": "Patent strategy: Strategic focus on the U.S. and Europe with extension into other geographical markets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "361d0228-f7eb-4f12-9851-dd4b7d80a212",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.04,
        "y": 0.73
      },
      "kind": "list",
      "text": "Soft barriers: Significant formulation and manufacturing know-how. Questionable relevance of bioequivalence studies. Nefecon is the most advanced candidate in development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f0e96bb-0de0-4442-85f3-753fbe7eb7a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "list",
      "text": "Orphan designation: Granted orphan drug designation in the U.S. and E.U. Potential data protection and market exclusivity for 7 years (U.S.) and 10 years (E.U.)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a3c9eca-6810-464a-8da6-9bdf00c96c35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "Existing patents: Calliditas has been granted patents covering Nefecon, its formulation and method of manufacturing. The formulation patent runs until 2029",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8aa14a72-408c-49d9-a1f3-0f2325d0b976",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Strong product protection and product exclusivity for Nefecon",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb187e89-7b27-4887-95d7-c4f467637a93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "moat-analysis",
      "slug": null,
      "matchId": "a4bcd647-1866-4794-8c3f-e006526d2ed3",
      "evidence": "Categorization of regulatory, patent, and operational barriers to entry.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "a29c6cb0-a5f7-4238-af02-25ffcbce3a70",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nefecon as a solution to the problem of IgA Nephropathy.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}